Beyond atezolizumab plus bevacizumab in patients with advanced hepatocellular carcinoma: overall efficacy and safety of tyrosine kinase inhibitors in a real-world setting.
Fiche publication
Date publication
août 2023
Journal
Therapeutic advances in medical oncology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr MANFREDI Sylvain
Tous les auteurs :
Falette-Puisieux M, Nault JC, Bouattour M, Lequoy M, Amaddeo G, Decaens T, Di Fiore F, Manfredi S, Merle P, Baron A, Locher C, Pellat A, Coriat R
Lien Pubmed
Résumé
In patients with advanced hepatocellular carcinoma (HCC) progressing after atezolizumab and bevacizumab, the optimal therapeutic sequence is still unclear and no second-line agent has proven its efficacy.
Mots clés
HCC, advanced hepatocellular carcinoma, regorafenib, sorafenib, tyrosine kinase inhibitors
Référence
Ther Adv Med Oncol. 2023 08 1;15:17588359231189425